Johnson & Johnson Hits New 52-Week High at $259.90, Showcasing Strong Growth

Johnson & Johnson has reached a significant milestone by hitting a new 52-week high of USD 259.90 on June 30, 2026. This achievement underscores the company's robust performance in the Pharmaceuticals & Biotechnology sector, where it holds a substantial market capitalization of USD 696,645 million, classifying it as a large-cap stock. Over the past year, Johnson & Johnson has demonstrated impressive growth, with a performance increase of 72.62%, significantly outpacing the S&P 500's 20.86% gain during the same period. The company's price-to-earnings (P/E) ratio stands at 31.00, reflecting its valuation in the market. Additionally, Johnson & Johnson maintains a healthy dividend yield of 1.94%, appealing to income-focused investors. The company's financial metrics further highlight its stability, with a debt-to-equity ratio of 0.34 and a return on equity of 27.89%. The stock's 52-week low was recorded at USD 152.81, marking a notable recovery and upward trend in its market performance.